Publications by authors named "İlksen Demir"
Reumatologia
December 2020
Article Synopsis
- The study focuses on evaluating serious adverse events in children with juvenile idiopathic arthritis who are treated with biologic agents.
- It includes data from 162 patients, primarily treated with etanercept, and identifies upper respiratory infections as the most common adverse event, with a serious adverse event rate of 6.7%.
- The research highlights the need to monitor potential severe health risks associated with biologic treatments, while indicating that overall, these therapies can effectively manage the disease.
